IVIG can administer intravenously in the dosage of 0.4 g/kg for five days to treat Guillainâ€“Barre syndrome, but the dose varies depending on the pathology. Cyclophosphamide low dose has had a more significant impact on cell-mediated immunity. In humans, a low-dose bolus 600 mg/m B cells decrease more than T cells, and among T cells, the CD8 subset diminishes more than CD4 cells.